Skip to main content
. 2021 Jun 28;10:16. doi: 10.4103/abr.abr_76_21

Table 1.

Characteristics of patients

n
Total number of assessable patients 23
Age at study entry, years 63.2±11.3
HER2/neu positive (%) 12
ER positive (%) 100
PR positive (%) 100
Grading (%)
 2 56.6
 3 43.4
Sites of metastases at study entry (%)
 Visceral 13.1
 Bone 86.9
 CTC+ 100
 Integrin β4+ CTCs+/total 61

HER2/neu: Human epidermal growth factor receptor 2, ER: Estrogen receptor, CTCs: Circulating tumor cells, PR: Progesterone receptor